Thrombolysis in pregnancy: a literature review
- 11 February 2018
- journal article
- review article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 32 (14) , 2418-2428
Abstract
Background: Changes in the coagulation system during pregnancy and puerperium produce a physiological hypercoagulable state. These changes are thought to be the cause of the higher rates of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and mechanical prosthetic valve thrombosis (PVT) during pregnancy. Thrombolysis can be a treatment option in this case. However, there are no available data from randomized controlled trials in pregnant patients and information about the security of thrombolytics in pregnancy is missing. Objective: The aim of this review is to summarize the available data regarding the use of thrombolytic agents in pregnancy, describing maternal and fetal outcomes. Methods: A systematic review was performed, searching the electronic database MEDLINE for relevant studies published up to April 2017. The search included MeSH terms “thrombolytic therapy” OR “fibrinolysis” OR “streptokinase” OR “tissue plasminogen activator” AND “pregnancy”. All publications that reported the use of a thrombolytic agent for DVT, PE, stroke or PVT in pregnancy were included in the review. Data on the type and total dose of the thrombolytic agent, gestational week, outcome of mothers and children, preterm delivery and bleeding complications were described. Results: Sixty-five articles have been published describing outcomes in 141 pregnant women with serious thrombotic events. There have been no randomized trials involving the use of thrombolytics in pregnancy. Only one prospective study was found. Four maternal deaths (2.8%), 12 major bleeding episodes (8.5%), 13 mild/moderate bleeding episodes (9.2%), two fetal death (1.4%), one child death (0.7%), nine miscarriages (6.4%), and 14 preterm delivery (9.9%) were described. Conclusions: The risk of using thrombolytics in pregnancy seems reasonable taking into account the risk of death in a life-threatening event, with the majority of cases presented in this article resulting in encouraging outcomes. The complication rate of thrombolytic treatment does not seem higher in pregnant women than in the nonpregnant. Poor fetal outcome occurred in mothers with poor prognosis. Specific consensus recommendations are needed in the use of thrombolytics in pregnancy.Keywords
This publication has 93 references indexed in Scilit:
- Thrombolysis for the management of massive pulmonary embolism in pregnancyInternational Journal of Obstetric Anesthesia, 2013
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Thrombolytic Therapy for Ischemic Stroke Secondary to Paradoxical Embolism in PregnancyThe Neurologist, 2012
- Thrombolysis for massive pulmonary embolism in pregnancy: a case reportInternational Journal of Emergency Medicine, 2011
- Intravenous Recombinant Tissue Plasminogen Activator in a Pregnant Woman With Cardioembolic StrokeStroke, 2006
- Technique of contemporary iliofemoral and infrainguinal venous thrombectomyJournal of Vascular Surgery, 2006
- Thrombosis during pregnancy and the postpartum periodAmerican Journal of Obstetrics and Gynecology, 2005
- Incidence of Stroke and Myocardial Infarction in Women of Reproductive AgeStroke, 1997
- Prosthetic mitral valve thrombosis in pregnancy successfully treated with streptokinaseAmerican Heart Journal, 1994
- Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labourIntensive Care Medicine, 1990